NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thank you for highlighting the most astonishing discovery of the DCVax P3—doubling rGBM survival. In fact, it was this discovery that prompted the Keytruda DCVax combo trial funded by NIH and Merck. GBM always becomes rGBM of course, so this discovery is of immeasurable significance.

RECURRENT GBM:

mOS: 13.2 mos vs. 7.8 mos from recurrence

Survival Tail: 20.7% vs. 9.6% at 24 mos after recurrence 11.1% vs. 5.1% at 30 mos after recurrence

https://virtualtrials.org/dcvax/dcvax.pdf